Skip to main content

Advertisement

Table 1 Subject-, disease-, and transplant-related variables

From: Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

CharacteristicsATG-PTCy cohort (n = 114)ATG cohort (n = 125)P value
Recipient age (year, median, range)27 (5–52)24 (4–65)0.004
HLA-matching (A, B, DR)0.001
 3/694 (82%)78 (62%) 
 4/6 or 5/620 (18%)47 (38%) 
Recipient gender0.35
 Male63 (55%)77 (62%) 
 Female51 (45%)48 (38%) 
Disease type0.99
 Acute myeloid leukemia (AML)55 (48%)59 (47%) 
 Acute lymphoblastic leukemia (ALL)47 (41%)52 (42%) 
 Myelodysplastic syndromes (MDS)9 (8%)11 (9%) 
 Chronic myeloid leukemia (CML)3 (3%)3 (2%) 
Disease risk index0.20
 Low/intermediate101 (88%)103 (83%) 
 High/very high13 (12%)22 (17%) 
Minimal residual disease at transplant0.86
 Negative93 (82%)104 (83%) 
 Positive21 (18%)21 (17%) 
Donor source0.19
 Mother80 (70%)98 (78%) 
 Collateral relatives34 (30%)27 (22%) 
  Donor gender male vs female27 vs 720 vs 7 
  Donor age (year, median, range)46 (12–67)42 (10–61) 
  Maternal vs paternal line20 vs 1419 vs 8 
Donor gender0.15
 Male27 (24%)20 (16%) 
 Female87 (76%)105 (84%) 
Donor-recipient pair0.20
 Female to male68 (60%)64 (51%) 
 Others46 (40%)61 (49%) 
Donor age (year, median, range)46 (12–67)42 (10–61)0.002
Blood type matching0.020
 Match51 (45%)75 (60%) 
 Mismatch63 (55%)50 (40%) 
Median mononuclear cell (range, 108/kg)8.2 (3.3–11.8)10.4 (3.8–26.1)< 0.001
Median CD34+ cells (range, 106/kg)1.9 (0.5–14.1))3.4 (1.6–21.2)< 0.001
Median CD3+ cells (range, 108/kg)1.4 (0.3–5.7)1.5 (0.3–11.1)0.63
Year of transplant0.006
 April 2015 to August 201640 (35%)66 (53%) 
 September 2016 to June 201874 (65%)59 (47%) 
Median follow-up (range, days)587 (57–1399)682 (3–1448)0.20
Median follow-up in survivors (range, days)661 (128–1399)859 (230–1448)0.007